Neovacs S.A.
Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

PRESS RELEASE

Neovacs to attend Jefferies 2016 London Healthcare Conference
November 16 & 17, 2016

Paris and Boston, November 3^rd, 2016 – Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hilton in London, UK.

This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world from the biotechnology, pharmaceutical, generic, consumer health, medical technology and Healthcare Service sectors. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 business-to-business and investor meetings.

The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1×1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

About Neovacs
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com

Investor Relations / Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com